Grifols expects European approval for Flebogamma 10 percent

Grifols has said its new ten percent intravenous immunoglobulin (IVIG) preparation should be approved in Europe before the end of 2010.

The company made the comment after announcing the availability of the Flebogamma ten percent DIF in the US, where it received approval from the Food and Drug Administration in July.

Developed at the firm's dedicated production facility in Barcelona, the new Flebogamma concentration follows the launch of the five percent DIF IVIG by Grifols in early 2007.

Company spokesperson Gregory Rich said the new product will help Grifols to meet "a wider range of clinical needs".

He added: "The clinical needs of patients are unique and by offering a choice of IVIG concentrations we can better address them."

To protect product integrity, each vial of Flebogamma ten percent DIF comes with a unique identification number laser etched on the side.

Grifols recently announced a turnover of 738.8 million euros for the first nine months of 2010, with third-quarter sales increasing by 14.6 percent on the previous year.